IFIH1 and dermatomyositis: In contrast to our study, which specifically targeted patients with anti-MDA5+DM-ILD, Lian et al’s [10] investigation encompassed a more expansive patient population, not restricting their analysis solely to anti-MDA5+DM-ILD cases.